Review article · 2023 · Open access

Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease

Yanan Xu, Hailun Jiang, Bin Zhu, Mingnan Cao, Tao Feng, Zhongshi Sun, Guanhua Du, Zhigang Zhao

CNS Neuroscience & Therapeutics, 29(8), 2060–2073 · Published 5 May 2023 · DOI 10.1111/cns.14238

Open PDFView at the publisherCite this paper

In brief

“Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease” is a 2023 review article by Yanan Xu and 7 co-authors, published in CNS Neuroscience & Therapeutics. OpenAlex counts 11 citations as of 19 November 2026, which puts it in the top 7% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at CNS Neuroscience & Therapeutics.

Citations
11
Most cited in
2026 (5)
Field-weighted impact
0.30
References
149
Authors
8

Abstract

AIMS: Alzheimer's disease (AD) is a neurodegenerative disease with challenging early diagnosis and effective treatments due to its complex pathogenesis. AD patients are often diagnosed after the appearance of the typical symptoms, thereby delaying the best opportunity for effective measures. Biomarkers could be the key to resolving the challenge. This review aims to provide an overview of application and potential value of AD biomarkers in fluids, including cerebrospinal fluid, blood, and saliva, in diagnosis and treatment. METHODS: A comprehensive search of the relevant literature was conducted to summarize potential biomarkers for AD in fluids. The paper further explored the biomarkers' utility in disease diagnosis and drug target development. RESULTS: , total Tau (t-Tau), and phosphorylated Tau (p-Tau), have been endorsed for their diagnostic and predictive capability. However, other biomarkers remain controversial. Drugs targeting Aβ have shown some efficacy and those that target BACE1 and Tau are still undergoing development. CONCLUSION: Fluid biomarkers hold considerable potential in the diagnosis and drug development of AD. However, improvements in sensitivity and specificity, and approaches for managing sample impurities, need to be addressed for better diagnosis.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Xu, Y., Jiang, H., Zhu, B., Cao, M., Feng, T., Sun, Z., Du, G., & Zhao, Z. (2023). Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease. CNS Neuroscience & Therapeutics, 29(8), 2060–2073. https://doi.org/10.1111/cns.14238

MLA 9

Xu, Yanan, et al. “Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease.” CNS Neuroscience & Therapeutics, vol. 29, no. 8, 2023, pp. 2060–2073. https://doi.org/10.1111/cns.14238.

Chicago

Xu, Yanan, Hailun Jiang, Bin Zhu, Mingnan Cao, Tao Feng, Zhongshi Sun, Guanhua Du, and Zhigang Zhao. 2023. “Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease.” CNS Neuroscience & Therapeutics 29 (8): 2060–2073. https://doi.org/10.1111/cns.14238.

Harvard

Xu, Y. et al. (2023) ‘Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease’, CNS Neuroscience & Therapeutics, 29(8), pp. 2060–2073. doi:10.1111/cns.14238.

IEEE

Y. Xu et al., “Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease,” CNS Neuroscience & Therapeutics, vol. 29, no. 8, pp. 2060–2073, 2023, doi: 10.1111/cns.14238.

BibTeX

@article{xu2023advances,
  title     = {{Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease}},
  author    = {Xu, Yanan and Jiang, Hailun and Zhu, Bin and Cao, Mingnan and Feng, Tao and Sun, Zhongshi and Du, Guanhua and Zhao, Zhigang},
  journal   = {CNS Neuroscience \& Therapeutics},
  year      = {2023},
  volume    = {29},
  number    = {8},
  pages     = {2060--2073},
  doi       = {10.1111/cns.14238},
  url       = {https://doi.org/10.1111/cns.14238}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202322
202422
202522
202655

Its field-weighted citation impact is 0.30: it has been cited 0.30 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • fluid biomarkers
  • cerebrospinal fluid
  • blood biomarkers
  • salivary biomarkers
  • total tau
  • phosphorylated tau
  • amyloid-beta

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Xu, Y., Jiang, H., Zhu, B., Cao, M., Feng, T., Sun, Z., Du, G., & Zhao, Z. (2023). Advances and applications of fluids biomarkers in diagnosis and therapeutic targets of Alzheimer's disease. CNS Neuroscience & Therapeutics, 29(8), 2060–2073. https://doi.org/10.1111/cns.14238

How many times has this paper been cited?

11 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at CNS Neuroscience & Therapeutics: sign in and open the PDF from this page.

Who wrote this paper?

Yanan Xu, Hailun Jiang, Bin Zhu, Mingnan Cao, Tao Feng, Zhongshi Sun, Guanhua Du, Zhigang Zhao.

What is the DOI of this paper?

10.1111/cns.14238, permanently at https://doi.org/10.1111/cns.14238. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.